Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer | Zendy

Jill J. Bastman | Zendy; Hilary S. Serracino | Zendy; Yuwen Zhu | Zendy; Michelle R. Koenig | Zendy; Valerica Mateescu | Zendy; Sharon B. Sams | Zendy; Kurtis D. Davies | Zendy; Christopher D. Raeburn | Zendy; Robert C. McIntyre | Zendy; Bryan R. Haugen | Zendy; Jena D. French | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

Author(s) -

Jill J. Bastman,

Hilary S. Serracino,

Yuwen Zhu,

Michelle R. Koenig,

Valerica Mateescu,

Sharon B. Sams,

Kurtis D. Davies,

Christopher D. Raeburn,

Robert C. McIntyre,

Bryan R. Haugen,

Jena D. French

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4227

Subject(s) - anaplastic thyroid cancer , medicine , thyroid cancer , foxp3 , thyroid , immunohistochemistry , cancer , pd l1 , cd8 , oncology , immune system , cancer research , pathology , immunotherapy , immunology

Five to 10% of patients with differentiated thyroid cancers (DTC) develop invasive and/or distant metastatic disease that is marginally improved with standard therapies. Prognosis is poor for patients with anaplastic thyroid cancer, with a median survival of 3-5 months. We suggest that a paradigm shift is necessary in the treatment of advanced cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research